$BDSX
BIODESIX INC

2020 Q4 Form 10-Q Financial Statement

#000156459020056735 Filed on December 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $27.03M $9.193M $24.55M
YoY Change 10.09% 133.21%
Cost Of Revenue $14.65M $3.890M $6.074M
YoY Change 141.19%
Gross Profit $12.38M $5.300M $18.48M
YoY Change -33.0%
Gross Profit Margin 45.8% 57.65% 75.26%
Selling, General & Admin $12.06M $7.879M $30.64M
YoY Change -60.64% -4.06%
% of Gross Profit 97.42% 148.66% 165.8%
Research & Development $3.110M $2.706M $10.47M
YoY Change -70.29% 14.71%
% of Gross Profit 25.12% 51.06% 56.65%
Depreciation & Amortization $730.0K $200.0K $1.410M
YoY Change -48.23% 0.0%
% of Gross Profit 5.9% 3.77% 7.63%
Operating Expenses $15.17M $15.43M $41.11M
YoY Change -63.09% 18.99%
Operating Profit -$2.790M -$6.240M -$22.63M
YoY Change -87.67% -30.88%
Interest Expense -$690.0K $2.658M -$2.953M
YoY Change -76.63% 276.49%
% of Operating Profit
Other Income/Expense, Net -$1.190M $53.00K -$1.032M
YoY Change 15.31% -60.15%
Pretax Income -$4.530M -$8.850M -$30.73M
YoY Change -85.26%
Income Tax
% Of Pretax Income
Net Earnings -$4.530M -$8.845M -$30.73M
YoY Change -85.26% -7.87%
Net Earnings / Revenue -16.76% -96.21% -125.15%
Basic Earnings Per Share
Diluted Earnings Per Share -$170.6K -$337.1K -$1.170M
COMMON SHARES
Basic Shares Outstanding 26.54M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.10M $6.300M
YoY Change
Cash & Equivalents $62.13M $6.300M $5.286M
Short-Term Investments
Other Short-Term Assets $8.710M $6.405M $2.122M
YoY Change 310.46%
Inventory
Prepaid Expenses
Receivables $15.30M $5.396M $5.292M
Other Receivables $0.00 $0.00
Total Short-Term Assets $86.14M $18.15M $12.70M
YoY Change 578.27%
LONG-TERM ASSETS
Property, Plant & Equipment $3.178M $3.005M $2.120M
YoY Change 49.91%
Goodwill $15.03M $11.63M $15.03M
YoY Change 0.0% 5.82%
Intangibles $13.26M $13.74M $15.16M
YoY Change -12.55%
Long-Term Investments
YoY Change
Other Assets $3.461M $100.0K $90.00K
YoY Change 3745.56%
Total Long-Term Assets $34.93M $28.40M $32.33M
YoY Change 8.03%
TOTAL ASSETS
Total Short-Term Assets $86.14M $18.15M $12.70M
Total Long-Term Assets $34.93M $28.40M $32.33M
Total Assets $121.1M $46.55M $45.03M
YoY Change 168.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.964M $3.485M $1.717M
YoY Change 422.07%
Accrued Expenses $7.789M $6.953M $4.180M
YoY Change 86.34%
Deferred Revenue $3.500M $5.673M $1.283M
YoY Change 172.8%
Short-Term Debt $0.00 $26.00M
YoY Change
Long-Term Debt Due $11.80M $7.200M
YoY Change
Total Short-Term Liabilities $32.13M $56.56M $22.60M
YoY Change 42.15%
LONG-TERM LIABILITIES
Long-Term Debt $15.90M $20.30M
YoY Change
Other Long-Term Liabilities $1.921M $392.0K $358.0K
YoY Change 436.59%
Total Long-Term Liabilities $47.78M $51.20M $53.61M
YoY Change -10.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.13M $56.56M $22.60M
Total Long-Term Liabilities $47.78M $51.20M $53.61M
Total Liabilities $79.90M $107.8M $76.21M
YoY Change 4.84%
SHAREHOLDERS EQUITY
Retained Earnings -$258.8M -$257.7M -$227.5M
YoY Change 13.78%
Common Stock $27.00K $2.000K $1.000K
YoY Change 2600.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.17M -$251.8M -$225.1M
YoY Change
Total Liabilities & Shareholders Equity $121.1M $46.55M $45.03M
YoY Change 168.85%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$4.530M -$8.845M -$30.73M
YoY Change -85.26% -7.87%
Depreciation, Depletion And Amortization $730.0K $200.0K $1.410M
YoY Change -48.23% 0.0%
Cash From Operating Activities -$8.760M -$3.770M -$11.95M
YoY Change -26.69%
INVESTING ACTIVITIES
Capital Expenditures -$550.0K -$1.310M -$570.0K
YoY Change -3.51%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$250.0K -$460.0K
YoY Change -100.0%
Cash From Investing Activities -$550.0K -$1.560M -$1.020M
YoY Change -46.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 65.07M 10.00K 12.99M
YoY Change 400.92%
NET CHANGE
Cash From Operating Activities -8.760M -3.770M -11.95M
Cash From Investing Activities -550.0K -1.560M -1.020M
Cash From Financing Activities 65.07M 10.00K 12.99M
Net Change In Cash 55.76M -5.320M 20.00K
YoY Change 278700.0%
FREE CASH FLOW
Cash From Operating Activities -$8.760M -$3.770M -$11.95M
Capital Expenditures -$550.0K -$1.310M -$570.0K
Free Cash Flow -$8.210M -$2.460M -$11.38M
YoY Change -27.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
us-gaap Interest Expense
InterestExpense
2005000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000
dei Amendment Flag
AmendmentFlag
false
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26541317
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
BDSX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Central Index Key
EntityCentralIndexKey
0001439725
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
15433000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
12970000
us-gaap Operating Expenses
OperatingExpenses
38809000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
118766273
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M17D
CY2020Q3 us-gaap Revenues
Revenues
9193000
CY2019Q3 us-gaap Revenues
Revenues
3942000
us-gaap Revenues
Revenues
18528000
us-gaap Revenues
Revenues
16281000
CY2020Q3 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
3891000
CY2019Q3 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
1503000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
7346000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
4244000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2706000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2359000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7713000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7966000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7879000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8212000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22793000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24080000
CY2020Q3 bdsx Accretion Of Contingent Consideration
AccretionOfContingentConsideration
957000
CY2019Q3 bdsx Accretion Of Contingent Consideration
AccretionOfContingentConsideration
896000
bdsx Accretion Of Contingent Consideration
AccretionOfContingentConsideration
2901000
bdsx Accretion Of Contingent Consideration
AccretionOfContingentConsideration
2525000
bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
-1944000
bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
663000
us-gaap Operating Expenses
OperatingExpenses
39478000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6240000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9028000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20281000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23197000
CY2020Q3 us-gaap Interest Expense
InterestExpense
2658000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
133000
CY2019Q3 us-gaap Interest Expense
InterestExpense
706000
us-gaap Interest Expense
InterestExpense
6899000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
363000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-31.93
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-39.35
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1001000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8845000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-9601000
us-gaap Net Income Loss
NetIncomeLoss
-26817000
us-gaap Net Income Loss
NetIncomeLoss
-24201000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-99.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-103.87
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
277000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
244000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
269000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
233000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6348000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5286000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5396000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5292000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
6405000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2122000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
18149000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
12700000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3005000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2120000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13667000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15092000
CY2020Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
95000
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
90000
CY2020Q3 us-gaap Goodwill
Goodwill
11631000
CY2019Q4 us-gaap Goodwill
Goodwill
11631000
CY2020Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
28398000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
28933000
CY2020Q3 us-gaap Assets
Assets
46547000
CY2019Q4 us-gaap Assets
Assets
41633000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3485000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1717000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6953000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5673000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1283000
CY2020Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
26600000
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
12159000
CY2020Q3 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
7202000
CY2020Q3 bdsx Put Option Liability Current
PutOptionLiabilityCurrent
6650000
CY2019Q4 bdsx Put Option Liability Current
PutOptionLiabilityCurrent
3261000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
56563000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22600000
CY2020Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
403000
CY2019Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
329000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
392000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
358000
CY2020Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
17236000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
23812000
CY2020Q3 bdsx Paycheck Protection Program Note Payable Noncurrent
PaycheckProtectionProgramNotePayableNoncurrent
3099000
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
30071000
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
29114000
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
51201000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
53613000
CY2020Q3 us-gaap Liabilities
Liabilities
107764000
CY2019Q4 us-gaap Liabilities
Liabilities
76213000
CY2020Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2503000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2324000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257681000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230864000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-255176000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-228539000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
202582000
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
289508
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
289508
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
254918
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
254918
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
185432719
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
174237067
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
118766273
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
118766273
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
118766273
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
118766273
CY2020Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
202582000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46547000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41633000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-228539000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9706000
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-238234000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8266000
CY2020Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-246445000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
100000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8845000
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-255176000
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
183962000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-198030000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31000
CY2019Q1 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
9997000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7744000
CY2019Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-205713000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-212519000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6856000
CY2019Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4283000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-14000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
45000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-9601000
CY2019Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193959000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-222059000
us-gaap Profit Loss
ProfitLoss
-26817000
us-gaap Profit Loss
ProfitLoss
-24201000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2174000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2080000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4389000
us-gaap Share Based Compensation
ShareBasedCompensation
155000
us-gaap Share Based Compensation
ShareBasedCompensation
125000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
31000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
957000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3188000
bdsx Accrued Interest On Notes Payable And Convertible Notes Payable
AccruedInterestOnNotesPayableAndConvertibleNotesPayable
1025000
bdsx Accrued Interest On Notes Payable And Convertible Notes Payable
AccruedInterestOnNotesPayableAndConvertibleNotesPayable
415000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
109000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
109000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
113000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
16000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
217000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-17000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-10000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5369000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1722000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4390000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
508000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12610000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15997000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1483000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
915000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
151000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
79000
bdsx Payments To Acquire Oncimmune
PaymentsToAcquireOncimmune
750000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2384000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-994000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
10000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
12955000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3085000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-10000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-14000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16055000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20031000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1061000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3040000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5469000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6094000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6530000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9134000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
1300000
bdsx Value Of Put Option Recorded At Issuance Of Convertible Notes Payable
ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable
3389000
us-gaap Interest Paid Net
InterestPaidNet
1400000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6300000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257700000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-255200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">(d) Use of Estimates</span></p> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Areas of the financial statements where estimates have the most significant effect include the valuation of contingent consideration and purchased technology related to the Company’s business acquisition, valuation of impairment of goodwill and long-lived assets, stock-based compensation, valuation of put option liabilities, and the valuation allowance related to net deferred tax assets. Actual results could differ from those estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
0
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<span style="text-decoration:underline;"> Concentration of Risk </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk from its accounts receivable related to services provided to its customers. Reimbursement on behalf of customers covered by Medicare accounted for 61% and 58% of the Company’s non-COVID-19 diagnostic test revenue for the nine months ended September 30, 2020 and 2019, respectively and represented 17% and 18% of the Company’s total accounts receivable as of September 30, 2020 and December 31, 2019, respectively. One services customer represented 10% and 44% of the Company’s total accounts receivable balance as of September 30, 2020 and December 31, 2019, respectively. Two diagnostic test customers represented 35% and 0% of the Company’s total accounts receivable balance as of September 30, 2020 and December 31, 2019, respectively.</p>
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
200000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
200000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q3 us-gaap Revenues
Revenues
9193000
CY2019Q3 us-gaap Revenues
Revenues
3942000
us-gaap Revenues
Revenues
18528000
us-gaap Revenues
Revenues
16281000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
143538000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
139973000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8845000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-9601000
us-gaap Net Income Loss
NetIncomeLoss
-26817000
us-gaap Net Income Loss
NetIncomeLoss
-24201000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
277000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
244000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
269000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
233000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15092000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-31.93
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-39.35
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-99.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-103.87
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9487000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8506000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6482000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6386000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3005000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2120000
CY2020Q3 us-gaap Depreciation
Depreciation
200000
CY2019Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
600000
CY2020Q3 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
74000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2019Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
71000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13667000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
489000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1944000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1938000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1936000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1927000
CY2020Q3 bdsx Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
5359000
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13593000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2688000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1165000
CY2020Q3 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
699000
CY2019Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
620000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3566000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2352000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
43000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6953000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
600000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
114000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
1000000
CY2020Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
26600000
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
12159000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
729000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
112000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1915000
CY2020Q3 us-gaap Other Notes Payable
OtherNotesPayable
6000
CY2019Q4 us-gaap Other Notes Payable
OtherNotesPayable
12000
CY2020Q3 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
238000
CY2019Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
170000
CY2020Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
349000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
458000
CY2020Q3 us-gaap Notes Payable
NotesPayable
24438000
CY2019Q4 us-gaap Notes Payable
NotesPayable
23812000
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
7202000
CY2020Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
17236000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
23812000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
10318000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12199000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2270000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
24787000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1600000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
246000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
828000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
40000
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
185432719
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
118766273
CY2020Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
202582000
us-gaap Conversion Of Stock Description
ConversionOfStockDescription
The holders of Series A-1, Series A-2, and Series A-3 (collectively, “Series A”); Series B and Series B-1 (collectively, “Combined Series B”); Series C; Series D; Series E; Series F, Series G, and Series H are entitled to convert their shares into common stock at the option of the holder, at any time, into fully paid and non‑assessable shares of common stock. The number of shares of common stock to which a holder of the Series A, Combined Series B, Series C, Series D, Series E, Series F, Series G, and Series H (collectively, “Series Preferred”) can convert is obtained by multiplying the conversion rate that is in effect by the number of shares of Series Preferred being converted. The conversion rate is determined by dividing the original issue price by the applicable conversion price (initially the original issue price for all classes of Series Preferred except Series B‑1, for which the conversion price is initially $2.75). As a result of the reverse stock split effected in October 2020, the conversion rate for the Series Preferred is 0.1684664 per share.  Following the closing of the IPO in October 2020, each share of Series Preferred automatically converted into shares of common stock (based on the then‑effective Series Preferred conversion price).
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
one vote for each share of common stock on an as‑if‑converted basis.
us-gaap Preferred Stock Redemption Terms
PreferredStockRedemptionTerms
Series Preferred stockholders are subject to automatic redemption in the consolidation or merger of the Company or sale of all or substantially all of the Company's assets in which the stockholders of the Company immediately prior to the transaction hold less than 50% of the outstanding securities of the surviving entity.
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1916000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
829000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.83
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
35000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.53
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2670000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.05
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2670000
CY2020Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.05
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1267000
CY2020Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0050
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
362000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
155000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
125000

Files In Submission

Name View Source Status
0001564590-20-056735-index-headers.html Edgar Link pending
0001564590-20-056735-index.html Edgar Link pending
0001564590-20-056735.txt Edgar Link pending
0001564590-20-056735-xbrl.zip Edgar Link pending
bdsx-10q_20200930.htm Edgar Link pending
bdsx-10q_20200930_htm.xml Edgar Link completed
bdsx-20200930.xsd Edgar Link pending
bdsx-20200930_cal.xml Edgar Link unprocessable
bdsx-20200930_def.xml Edgar Link unprocessable
bdsx-20200930_lab.xml Edgar Link unprocessable
bdsx-20200930_pre.xml Edgar Link unprocessable
bdsx-ex311_718.htm Edgar Link pending
bdsx-ex312_719.htm Edgar Link pending
bdsx-ex31_716.htm Edgar Link pending
bdsx-ex321_720.htm Edgar Link pending
bdsx-ex322_721.htm Edgar Link pending
bdsx-ex32_717.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending